RxDoctor Payments Data

Stephen Broughton, MD

Interventional Cardiology · Little Rock, ARNPI 1215314877

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (56.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Abbott at 38.0% of the total. Reporting peaked in 2022 at $23,079 and has fallen 94.1% since, to $1,356 in 2025. Among interventional cardiology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,554in general payments, 2019–2025

Across 170 payments — averaging $197.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$13K
  • Medtronic$11K
  • Edwards Lifesciences$5K
  • Boston Scientific$2K
  • W. L. Gore & Associates, Inc.$1K
  • Shockwave Medical, Inc$465
  • plus $1K from 13 others

What the payments were for

  • Grants$19,00257%
  • Travel & lodging$8,07624%
  • Food & beverage$6,21619%
  • Education$2601%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,554 in reported general payments places this provider in the 90th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$82,984
Medicare patients
232
Services billed
950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan47$31,473
EliquisApixaban31$16,459
JardianceEmpagliflozin20$13,632
BrilintaTicagrelor11$7,484
Rosuvastatin Calcium31$475
Metoprolol Succinate56$397
Carvedilol69$381
Atorvastatin Calcium78$360
Chlorthalidone23$332
Nifedipine ErNifedipine17$209
Ezetimibe15$202
ClopidogrelClopidogrel Bisulfate28$196
Isosorbide Mononitrate ErIsosorbide Mononitrate22$187
Losartan Potassium21$185
Bumetanide12$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$36$31,47347 claims
AstraZenecaBrilinta$14$7,48411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →